Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects

被引：18

作者：

Xie, HG ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Nashville, TN 37240 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1997年 / 62卷 / 06期

关键词：

D O I：

10.1016/S0009-9236(97)90088-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：691 / 692

页数：2

共 11 条

[1] WHY ARE DIAZEPAM METABOLISM AND POLYMORPHIC S-MEPHENYTOIN HYDROXYLATION ASSOCIATED WITH EACH OTHER IN WHITE AND KOREAN POPULATIONS BUT NOT IN CHINESE POPULATIONS [J].

BERTILSSON, L ;

KALOW, W .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :608-610

[2]

BROCKMOLLER J, 1995, PHARMACOGENETICS, V5, P80

[3] Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].

Chang, M ;

Dahl, ML ;

Tybring, G ;

Gotharson, E ;

Bertilsson, L .

PHARMACOGENETICS, 1995, 5 (06) :358-363

[4] Meta-analysis: A method for synthesizing research [J].

DAgostino, RB ;

Weintraub, M .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) :605-616

[5]

DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594

[6]

DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419

[7] GENETIC-ANALYSIS OF THE S-MEPHENYTOIN POLYMORPHISM IN A CHINESE POPULATION [J].

DEMORAIS, SMF ;

GOLDSTEIN, JA ;

XIE, HG ;

HUANG, SL ;

LU, YQ ;

XIA, H ;

XIAO, ZS ;

ILE, N ;

ZHOU, HH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :404-411

[8]

Hoskins J. M., 1997, Clinical Pharmacology and Therapeutics, V61, P226

[9]

Xiao ZS, 1997, J PHARMACOL EXP THER, V281, P604

[10] Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: A meta-analysis [J].

Xie, HG ;

Xu, ZH ;

Luo, XA ;

Huang, SL ;

Zeng, FD ;

Zhou, HH .

PHARMACOGENETICS, 1996, 6 (03) :235-238

← 1 2 →